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Book Reviews
Reducing the Risk of Cancers
Open University Individual Study Pack P578S, Milton
Keynes: Open University, 1992.
How should an Open University course on 'Reducing the
Risk of Cancer' best present its subject matter? It might do
well to base itself on The Causes ofCancer by Doll and Peto.
This course, seemingly intended mainly for those in health
education, unfortunately does badly. The 'individual study
pack' consists of two readers (200 pages each), two audio
cassettes, an activity booklet (50 hours of activities) and a
workbook. The course dispenses not only with Doll and
Peto's book but with the analytical approach that the book
fosters, and adopts what seems to be an increasing trend in
contemporary education, sacrificing factual material for
opinion, controversy and discussion. We listen, for example,
to a 15-min consultation between 'Adam Forman', a general
practitioner, and 'Pam', a professional women (who lacks a
surname!), on Pam's eating habits ('make notes as you
listen'). We do not ask whether the advice would reduce the
risk of cancer, but we consider what techniques Adam uses
to persuade Pam, the main features of his plan and how Pam
is helped by Adam. Next we hear Adam and Pam talking
separately about the useful points of the consultation, and
finally we 'turn to our workbooks for feedback on this
activity'.
Even if we accept such one-to-one consultations with
healthy individuals as a realistic basis for preventing cancers
it is difficult to envisage the facile approach of the course
producing useful results. With such a large amount of
material on the prevention of cancer the dearth of factual
matter is alarming. There is scarcely more than a page on
mammographic screening for breast cancer, no account of
the trials, no estimate of the percentage reduction in breast
cancer mortality that is likely to result from the National
Screening Programme in Britain. With its inclination to
activity and discussion rather than reading and study the
course might encourage an informed discussion among its
students on whether the reduction in breast cancer mortality
justifies the costs of screening, and introduce formal means of
addressing the issue. But the activities are superficial.
Much of the interest in the subject of preventing cancer is
lost with the dilution of factual material. There is little on the
wide variation in incidence of many cancers around the
world, little on the genetics of cancer, little on theories of
exponential cancer growth or how an apparently early detec-
tion of cancer may represent just one doubling time of a
cancer that has experienced 30. Smoking gets more space, but
the approach remains superficial and judgement gives way,
even here, to a perceived need to present both sides of an
argument; thus a 'case for tobacco' is presented, which
includes the statement that 'the tobacco industry is philan-
thropic and generous'. There is a guide to monthly testicular
self-examipation, graphically illustrated but without discus-
sion on the lack of evidence that it would reduce mortality.
Consensus conferences are espoused rather than guidelines
on how an individual might assess evidence. We are told of
cancer-prone personality types, that emotionally suppressed
women develop breast cancer and controlled, conforming,
non-aggressive women develop gynaecological cancers, but
the difficulties in making such conclusions from psychological
assessments on cancer patients and controls are not dis-
cussed, nor the limited potential in prevention.
It is worrying to see the Open University trivialising an
important subject that should enthuse and stimulate, but the
trend is widespread, shared for example by some material
produced on behalf of the Department of Health. The end
result can only be to obfuscate the distinction between what
has been proven and what has not, to invite cynicism on
preventative measures and to weaken the impact of steps that
individuals, society and governments can take to reduce the
burden of cancers and other serious diseases.
M. Law
Therapy of Haemopoietic Neoplasia
Edited by E.J. Freireich & H. Kantarjian, New York: Marcel
Dekker, 1991, 456 pp. $150.00.
This book is unequivocally out of the M.D. Anderson stable
(14 out of the 15 authors are from there). That it is possible
to write such a book from a single institution at all is a
tribute to the tremendous contribution made there to cancer
therapy during its relatively short 50 year existence. The
book is a fitting statement of the M.D. Anderson philosophy
of developmental therapeutics, central to which, it must be
recorded, was the contribution over many years of Ken
McCredie, who has now sadly died. It is also unequivocally a
book for experts. There are no introductory concessions for
the novice, so those unfamiliar with the meaning of '3 + 7'
should proceed no further!
The book is divided into 11 chapters covering the major
haematopoietic disease groups - AML, MDS, ALL (adults
only), CGL, CLL, myeloma, HCL, Hodgkin's and NHL and
then two final chapters on supportive care and the manage-
ment of infectious complications. All the chapters are written
by acknowledged authorities in their field, and this is
reflected in the wealth of experience recorded here that makes
it very much a practising clinicians' book.
There are some imbalances. ALL - never a favourite M.D.
Anderson disease and the only chapter written by someone
from out of town - takes up only 16 pages of text, whereas
CGL takes up 70. The discussion of BMT in AML might be
regarded by the connoisseur as reflecting traditional M.D.
Anderson differences of opinion in this field, and to my mind
underplays the role of BMT in AML. However, those of us
who know and love the institution can forgive these little
peccadillos, as a vast amount of useful information is pres-
ented throughout the book in a clear fashion. I particularly
liked the use in some chapters of treatment guidelines for
subgroups of disease and for certain regimens, for example
when to use interferon as opposed to deoxycoformycin in
HCL.
The most difficult area to discuss and present clearly is
always NHL because of the heterogeneity of the disease.
Fernando Cabanillas, however, has written an excellent
account, although the mixture of Rappaport and Working
Formulation short-hand terms may be confusing at first sight
to UK and other European colleagues. I was surprised not to
read more about the platinum/Ara-C combinations (another
M.D. Anderson 'discovery') in this chapter, but was less
surprised to see no mention of allografting at all!
Supportive care has also made an important impact, par-
ticularly during high-dose intensification; indeed, the original
IBM cell separators were developed in conjunction with the
M.D. Anderson team. Short sections within the chapter dis-
cuss blood product support, the management oftumour lysis,
mucosistis and the emerging role of growth factors. Infect-
ions are dealt with in an unusual way - by disease group and
then again by site of infection, with a final section on pro-
phylaxis.
The whole book is heavily referenced and has a good
number ofdiagrams and illustrations to complement the text.
I can agree with the editors that it represents the current
'state of the art' for treatment, though for how long remains
to be seen. In conclusion, despite its price, I would strongly